NEO (NeoGenomics) Other Financing: $-201.3 Mil (TTM As of Mar. 2026)


NEO NeoGenomics Inc NEO
71 GF Score
Price $14.25
GF Value $16.58
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is NeoGenomics Other Financing?

NeoGenomics NEO +0.56% 71 Other Financing is $-201.3 Mil as of Mar. 2026. GuruFocus rates NEO with a GF Score™ of 71/100 and a GF Value™ of $16.58 (Modestly Undervalued). The stock has 6 warning signs investors should review.

NeoGenomics's Other Financing for the three months ended in Mar. 2026 was $0.0 Mil.

NeoGenomics's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was $-201.3 Mil.

NeoGenomics Other Financing Historical Data

* Premium members only.

The historical data trend for NeoGenomics's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeoGenomics Other Financing Chart

NeoGenomics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -32.34 -0.76 -0.07 0.00 0.00

NeoGenomics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -201.25 0.00 0.00 0.00
NEO
71GF Score
NeoGenomics Inc NEO
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NeoGenomics Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-201.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of $-201.3 Mil mean?
NeoGenomics (NEO) has a Other Financing of $-201.3 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for NeoGenomics and its competitors.
Is NeoGenomics' Other Financing too high?
NeoGenomics' current Other Financing is $-201.3 Mil. Overall, NeoGenomics has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does NeoGenomics' Other Financing compare to WGS and CDNA?
NeoGenomics' Other Financing of $-201.3 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Medical Diagnostics & Research company?
A good Other Financing depends on the Medical Diagnostics & Research industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for NeoGenomics and its competitors. NeoGenomics's current Other Financing is $-201.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeoGenomics stock overvalued right now?
Based on GuruFocus' analysis, NeoGenomics (NEO) is currently considered Modestly Undervalued. The stock's GF Value™ is $16.58, compared to a current price of $14.25 — trading 14.1% below its estimated fair value. The current Other Financing is $-201.3 Mil. NeoGenomics' overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For NeoGenomics (NEO), the current Other Financing is $-201.3 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NeoGenomics (NEO) Overvalued in 2026?

Based on GuruFocus' analysis, NeoGenomics stock appears to be undervalued. The current stock price of $14.25 is trading 14.1% below its estimated GF Value™ of $16.58. GuruFocus considers NeoGenomics to be Modestly Undervalued.

Key valuation signals for NEO:

  • Other Financing: $-201.3 Mil
  • GF Value™: $16.58 vs. price of $14.25 (14.1% below fair value)
  • GF Score™: 71/100 with 6 warning signs

No single metric tells the full story. See the NEO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NeoGenomics Business Description

Other Exchanges NEO:MexicoNG9:Germany
Address 9490 NeoGenomics Way, Fort Myers, FL, USA, 33912
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
71GF Score

Get the complete analysis for NEO

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.25
Price
$16.58
GF Value